Three new trials of HIV prevention drugs seek to answer directly a question that researchers inside and outside the field of HIV have explicitly avoided for years: How do drugs work -- and are they safe -- in pregnant and breastfeeding women?
The Infectious Diseases Society of America reported on June 29, 2018, that a new HIV acquisition had been found in a person using pre-exposure prophylaxis (PrEP).
The new maps from AIDSVu show more than 77,000 people were prescribed PrEP in 2016, with an average 73 percent increase year over year in persons using PrEP across the U.S. from 2012.
With black women at far greater risk for HIV than women of any other race or ethnicity, health organizations should think more creatively about how to bring them HIV and PrEP information.
It's time that patients, providers, pharmaceutical companies and the public health community have honest and difficult conversations about condoms, PrEP and bodily pleasure.
A recent study, published this month in JAIDS, gives insight into the challenges of PrEP uptake by young gay men of color.
Keiko Lane, M.F.T., finds herself connecting over the pain of losing so many to AIDS, even as she shares today's HIV prevention options with a gay, immigrant hotel worker in a serodiscordant relationship.
Linda-Gail Bekker provides an overview of the new frontiers in HIV prevention.